Fund Name

$ Value

% Port.

COM NEW

$ Bought

% Increased

% Reduced

$ Sold

Shares

Percent

Date

Type

% Portfolio

% Chg

$ Change

$ Held

# Shares

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-system...

Datesorted ascending	Fund Name	Type	% Portfolio	% Chg	$ Change	$ Held	# Shares
2024-05-15	Tower Research Capital LLC (TRC)	REDUCED	Premium	Premium	Premium	Premium	2,393
2024-05-15	ARMISTICE CAPITAL, LLC	NEW	Premium	Premium	Premium	Premium	27,000
2024-05-13	GEODE CAPITAL MANAGEMENT, LLC	NEW	Premium	Premium	Premium	Premium	10,847
2024-05-13	UBS Group AG	SOLD OFF	Premium	Premium	Premium	Premium	-
2024-05-10	WELLS FARGO & COMPANY/MN	ADDED	Premium	Premium	Premium	Premium	13.00
2024-05-08	US BANCORP \DE\	UNCHANGED	Premium	Premium	Premium	Premium	1.00
2024-05-01	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	SOLD OFF	Premium	Premium	Premium	Premium	-
2024-05-01	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	SOLD OFF	Premium	Premium	Premium	Premium	-
2024-04-17	Kathleen S. Wright Associates Inc.	UNCHANGED	Premium	Premium	Premium	Premium	1.00
2024-02-26	Virtu Financial LLC	SOLD OFF	Premium	Premium	Premium	Premium	-

Fund Name	# Shares	$ Value	% Port.
ARMISTICE CAPITAL, LLC	27,000	118,260	-
GEODE CAPITAL MANAGEMENT, LLC	10,847	48,269	-
Tower Research Capital LLC (TRC)	2,393	10,481	-
WELLS FARGO & COMPANY/MN	13.00	57.00	-
Kathleen S. Wright Associates Inc.	1.00	4.00	-
US BANCORP \DE\	1.00	4.00	-
Virtu Financial LLC	-	-	-
CONCOURSE FINANCIAL GROUP SECURITIES, INC.	-	-	-
CONCOURSE FINANCIAL GROUP SECURITIES, INC.	-	-	-
UBS Group AG	-	-	-

Fund Name	$ Value	% Port.
Virtu Financial LLC	-	-
Kathleen S. Wright Associates Inc.	4.00	-
CONCOURSE FINANCIAL GROUP SECURITIES, INC.	-	-
CONCOURSE FINANCIAL GROUP SECURITIES, INC.	-	-
US BANCORP \DE\	4.00	-
WELLS FARGO & COMPANY/MN	57.00	-
GEODE CAPITAL MANAGEMENT, LLC	48,269	-
UBS Group AG	-	-
Tower Research Capital LLC (TRC)	10,481	-
ARMISTICE CAPITAL, LLC	118,260	-

Fund Name	$ Bought
ARMISTICE CAPITAL, LLC	118,260
GEODE CAPITAL MANAGEMENT, LLC	48,269

Fund Name	$ Sold
UBS Group AG	-6,455
CONCOURSE FINANCIAL GROUP SECURITIES, INC.	-
CONCOURSE FINANCIAL GROUP SECURITIES, INC.	-
Virtu Financial LLC	-15,000

FWBI - First Wave BioPharma, Inc. Stock Price, Fair Value and News

Which funds bought or sold FWBI recently?

Which funds are the top buyers of FWBI?

Which funds have put a big percent of portfolio in FWBI?

Trend of No. of funds that hold FWBI

Changes in Positions

Investor Breakout

Investor Churn (# Increased Holdings)

New Buys

Additions

Reductions

Sold off